BioMarin Pharma (BMRN) reported third quarter earnings of $6.6 million or 6 cents per share on a GAAP basis, higher than $0.8 million or 1 cent per share last year. The company's adjusted earnings were higher at $15.5 million or 13 cents per share compared with $8.2 million or 8 cents per share in the year-ago period.
On average, 19 analysts polled by Thomson Reuters expected earnings of 1 cent per share. Analysts' estimates typically exclude one-time items.
Revenues rose to $80.81 million from the year-ago's $72.65 million. Analysts, on average, expected revenues of $81.92 million.
For the full year, the company guided revenues to $313 million to $327 million, an upward revision from its earlier estimate of $311 million to $336 million. The company also lifted its non-GAAP earnings guidance to $39.8 million to $43.8 million from its earlier estimate of $35.4 million to $41.4 million.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.